HIV patients get new hope against hepatitis b with tailored vaccine strategy

NCT ID NCT00480792

Completed ⭐️ VACCINE ⭐️ Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested three different ways of giving the hepatitis B vaccine to 437 people with HIV whose CD4 counts were above 200. The goal was to see which schedule—standard dose, double dose, or skin injections—works best to protect them from hepatitis B, a virus that can cause serious liver damage in HIV patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GenHevac B Pasteur (hepatitis B vaccine)
What this could lead to: If successful, this could identify a more effective hepatitis B vaccination schedule for people with HIV, reducing their risk of severe liver disease.
What could go wrong: This trial is completed, so results are available. However, the vaccine may still be less effective in some HIV patients, and protection may not last long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease hepatitis B virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Hopital Cochin CIC de vaccinologie

Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.